154-42-7 - Names and Identifiers
Name | 2-Amino-6-purinethiol
|
Synonyms | tioguanine THIOGUANINE 6-THIOGUANINE complex coenzyme 6-MERCAPTOGUANINE m m Thioguatzinum 5'-ribonucleotide 2-AMINO-6-PURINETHIOL 2-Amino-6-purinethiol 2-AMINO-6-MERCAPTOPURINE 2-aminopurine-6(1h)-thione 2-amino-purine-6(1h)-thion 2-amino-7H-purine-6-thiolate dibutyryl cyclic AMP calcium salt 2-amino-6-mercaptopurine crystalline 2-amino-1,7-dihydro-6h-purin-6-thion 2-amino-1,7-dihydro-6h-purine-6-thion 2-Amino-6-purinethiol (6-Thioguanine) 2-amino-3,5-dihydro-6H-purine-6-thione 2-amino-3,7-dihydro-6H-purine-6-thione 2-Amino-6-mercaptopurine, 2-Amino-6-purinethiol 2-amino-6-mercaptopurine (50X)*gamma-irradiated C
|
CAS | 154-42-7
|
EINECS | 205-827-2 |
InChI | InChI=1/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)/p-1 |
154-42-7 - Physico-chemical Properties
Molecular Formula | C5H5N5S
|
Molar Mass | 167.19 |
Density | 1.483 (estimate) |
Melting Point | ≥300°C(lit.) |
Boling Point | 555.4±42.0 °C(Predicted) |
Flash Point | 356°C |
Water Solubility | soluble |
Solubility | Practically insoluble in water and in ethanol (96%). It dissolves in dilute solutions of alkali hydroxides. |
Vapor Presure | 1.5E-17mmHg at 25°C |
Appearance | odorless or nearly odorless pale yellow crystalline powder |
Color | Yellow to green |
Merck | 14,9337 |
BRN | 157765 |
pKa | pKa 8.22 (Uncertain) |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMF may be stored at -20°C for up to 1 month. |
Refractive Index | 1.5605 (estimate) |
MDL | MFCD00233553 |
Physical and Chemical Properties | White or yellowish powder, umami, soluble in water, difficult to dissolve in ethanol, acetone and other organic solvents. |
Use | Anti-tumor. |
154-42-7 - Risk and Safety
Risk Codes | R25 - Toxic if swallowed
R23/24/25 - Toxic by inhalation, in contact with skin and if swallowed.
|
Safety Description | S28 - After contact with skin, wash immediately with plenty of soap-suds.
S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
S28A -
|
UN IDs | UN 2811 6.1/PG 3 |
WGK Germany | 3 |
RTECS | UP0740000 |
FLUKA BRAND F CODES | 13 |
HS Code | 29335990 |
Hazard Note | Irritant |
Hazard Class | 6.1 |
Packing Group | III |
Toxicity | LD50 oral in mouse: 160mg/kg |
154-42-7 - Reference
Reference Show more | 1. Hou, Changsheng, et al. "Effect of 6‐thioguanine, as an electrolyte additive, on the electrochemical behavior of an Al–air battery." Materials and Corrosion 71.9 (2020): 1480-1487.https://doi.org/10.1002/maco.202011542 |
154-42-7 - Nature
Open Data Verified Data
- This product is light yellow crystalline powder; Odorless or almost odorless. Insoluble in water, ethanol or chloroform; Soluble in dilute sodium hydroxide solution.
- This product is purine Antimetabolite. After being converted into the corresponding nucleotides in vivo, it can inhibit the synthesis of purine nucleotides; Its metabolic pathway is similar to that of mercaptopurine, which is a kind of DNA base, it can be incorporated into a DNA molecule as a wrong base, thus affecting the synthesis and function of DNA. It mainly acts on S phase, is a cycle specific drug, and has cross resistance to mercaptopurine, but the toxicity is small. In vivo metabolic pathways are: after methylation to become 2-amino -6-thiopurine, after the amino group to become 2-hydroxy -6-mercaptopurine, part of the oxidation to thiouric acid form is excreted in the urine.
Last Update:2024-01-02 23:10:35
154-42-7 - Preparation Method
Open Data Verified Data
prepared from guanine by substitution reaction of diphosphorus pentasulfide in the presence of ammonium hydroxide with pyridine.
Last Update:2022-01-01 11:12:25
154-42-7 - Introduction
Soluble in NaOH solution.
Last Update:2022-10-16 17:14:08
154-42-7 - Use
Open Data Verified Data
- Anti-tumor drug. For the treatment of various types of leukemia, acute leukemia is more commonly used.
- usage and dosage in combination with cytarabine, daunorubicin and prednisone have good curative effect on adult acute non-lymphocytic leukemia. Oral, 2~2.5 mg per kilogram of body weight per day, once or divided, 5~7 days for a course of treatment.
- light shielding, sealed storage.
Last Update:2022-01-01 11:12:25